Search results for " Selection"

showing 10 items of 1271 documents

Human leukocyte antigen-E mismatch is associated with better hematopoietic stem cell transplantation outcome in acute leukemia patients

2017

The immunomodulatory role of human leukocyte antigen (HLA)-E in hematopoietic stem cell transplantation (HSCT) has not been extensively investigated. To this end, we genotyped 509 10/10 HLA unrelated transplant pairs for HLA-E, in order to study the effect of HLA-E as a natural killer (NK)-alloreactivity mediator on HSCT outcome in an acute leukemia (AL) setting. Overall survival (OS), disease free survival (DFS), relapse incidence (RI) and non-relapse mortality (NRM) were set as endpoints. Analysis of our data revealed a significant correlation between HLA-E mismatch and improved HSCT outcome, as shown by both univariate (53% vs. 38%, P=0.002, 5-year OS) and multivariate (hazard ratio (HR)…

0301 basic medicineOncologyAdultMalemedicine.medical_specialtyTransplantation ConditioningAdolescentGenotypemedicine.medical_treatment610Hematopoietic stem cell transplantationHuman leukocyte antigen600 Technik Medizin angewandte Wissenschaften::610 Medizin und GesundheitArticle03 medical and health sciencesYoung Adult0302 clinical medicineCell Therapy & ImmunotherapyInternal medicineMedicineHumansTransplantation Homologousddc:610Potassium Channels Inwardly RectifyingSurvival analysisAllelesAgedBone Marrow TransplantationAcute leukemiabusiness.industryDonor selectionHistocompatibility TestingHazard ratioHistocompatibility Antigens Class IHematopoietic Stem Cell TransplantationHematologyMiddle Agedmedicine.diseasePrognosisSurvival AnalysisTransplantationLeukemiaLeukemia Myeloid Acute030104 developmental biologyTreatment OutcomeImmunologyFemalebusiness030215 immunology
researchProduct

Defining aggressive or early progressing nononcogene-addicted non-small-cell lung cancer: a separate disease entity?

2019

A substantial proportion of patients with nononcogene-addicted non-small-cell lung cancer (NSCLC) has ‘aggressive disease’, as reflected in short time to progression or lack of disease control with initial platinum-based chemotherapy. Recently, clinical correlates of aggressive disease behavior during first-line therapy have been shown to predict greater benefit from addition of nintedanib to second-line docetaxel in adenocarcinoma NSCLC. Positive predictive effects of aggressive disease have since been reported with other anti-angiogenic agents (ramucirumab and bevacizumab), while such features may negatively impact on outcomes with nivolumab in nonsquamous NSCLC with low PD-L1 expression…

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyIndolesLung NeoplasmsTime FactorsBevacizumabmedicine.medical_treatmentDocetaxelAntibodies Monoclonal HumanizedDisease-Free SurvivalRamucirumab03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansLung cancerLungChemotherapybusiness.industryPatient SelectionAntibodies MonoclonalGeneral Medicinemedicine.diseaserespiratory tract diseasesBevacizumab030104 developmental biologyOncologychemistryDocetaxel030220 oncology & carcinogenesisDisease ProgressionAdenocarcinomaNintedanibNivolumabbusinessmedicine.drugFuture oncology (London, England)
researchProduct

Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients’ selection

2018

The identification of reliable predictive biomarkers of efficacy or resistance to immune-oncology (I–O) agents is a major issue for translational research and clinical practice. However, along with PDL1 and molecular features other clinical, radiological and laboratory factors can be considered for the selection of those patients who would not be the best candidate for immune-checkpoint inhibitors (ICPIs). We examined these factors, emerging from the results of currently available studies in non-small cell lung cancer (NSCLC), aiming to provide a useful and manageable tool which can help Oncologists in their everyday clinical practice. A thorough patient evaluation and close clinical monito…

0301 basic medicineOncologymedicine.medical_specialtyLung NeoplasmsImmune-checkpoint inhibitorSettore MED/06 - Oncologia MedicaImmune-checkpoint inhibitorsBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Antibodies Monoclonal; B7-H1 Antigen; Biomarkers; CTLA-4 Antigen; Carcinoma Non-Small-Cell Lung; Humans; Immunotherapy; Lung Neoplasms; Patient Selection; Hematology; OncologyAntibodiesB7-H1 Antigen03 medical and health sciences0302 clinical medicineNon-small cell lung cancerCarcinoma Non-Small-Cell LungInternal medicineMonoclonalmedicineHumansCTLA-4 AntigenNeutrophil to lymphocyte ratioNon-Small-Cell LungLung cancerHepatitisPerformance statusbusiness.industryPatient SelectionCarcinomaInterstitial lung diseaseAntibodies MonoclonalBronchiolitis obliterans organizing pneumoniaBiomarkerHematologymedicine.diseaseBiomarkers; Immune-checkpoint inhibitors; Immune-oncology; Non-small cell lung cancer; Predictive factors; Hematology; OncologyClinical trial030104 developmental biologyOncology030220 oncology & carcinogenesisImmunotherapyPredictive factorbusinessBiomarkersImmune-oncologyPredictive factorsProgressive diseaseCritical Reviews in Oncology/Hematology
researchProduct

2019

Background Body fat and/or muscle composition influences prognosis in several cancer types. For advanced gastric and gastroesophageal junction cancer, we investigated which body composition parameters carry prognostic information beyond well-established clinical parameters using robust model selection strategy such that parameters identified can be expected to generalize and to be reproducible beyond our particular data set. Then we modelled how differences in these parameters translate into survival outcomes. Methods Fat and muscle parameters were measured on baseline computed tomography scans in 761 patients with advanced gastric or gastroesophageal junction cancer from the phase III EXPA…

0301 basic medicineOncologymedicine.medical_specialtyMultivariate analysisProportional hazards modelbusiness.industryModel selectionCancermedicine.diseaseCorrelation03 medical and health sciences030104 developmental biology0302 clinical medicine030220 oncology & carcinogenesisPhysiology (medical)SarcopeniaInternal medicineCohortmedicineOrthopedics and Sports MedicinebusinessSurvival analysisJournal of Cachexia, Sarcopenia and Muscle
researchProduct

Is ovarian cancer a targetable disease? A systematic review and meta-analysis and genomic data investigation

2016

// Nicoletta Staropoli 1, * , Domenico Ciliberto 1, * , Silvia Chiellino 1 , Francesca Caglioti 1 , Teresa Del Giudice 1 , Simona Gualtieri 1 , Angela Salvino 1 , Alessandra Strangio 1 , Cirino Botta 1 , Sandro Pignata 2 , Pierfrancesco Tassone 1, * , Pierosandro Tagliaferri 1, * 1 Department of Experimental and Clinical Medicine, Magna Graecia University, Catanzaro, Italy 2 Department of Gynecologic and Urologic Oncology, Fondazione Pascale, National Cancer Institute of Naples, Naples, Italy * These authors have contributed equally to this work Correspondence to: Pierosandro Tagliaferri, email: tagliaferri@unicz.it Keywords: ovarian cancer, targeted therapy, systemic chemotherapy, systemat…

0301 basic medicineOncologymedicine.medical_specialtyTime FactorsBevacizumabmedicine.medical_treatmentAngiogenesis InhibitorsDisease-Free SurvivalTargeted therapyTargeted therapy03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRisk FactorsOvarian cancerInternal medicineBiomarkers TumorOdds RatiomedicineHumansMeta-analysiMolecular Targeted TherapyPrecision MedicineSystemic chemotherapyOvarian Neoplasmsbusiness.industryPatient SelectionHazard ratioCancermedicine.diseaseCarboplatinmeta-analysisClinical trialTreatment Outcome030104 developmental biologyOncologychemistryDrug Resistance Neoplasm030220 oncology & carcinogenesisMeta-analysisDisease ProgressionSystematic reviewFemalePersonalized medicinebusinessResearch PaperSignal Transductionmedicine.drug
researchProduct

Consequences of organ choice in describing bacterial pathogen assemblages in a rodent population

2017

SUMMARYHigh-throughput sequencing technologies now allow for rapid cost-effective surveys of multiple pathogens in many host species including rodents, but it is currently unclear if the organ chosen for screening influences the number and identity of bacteria detected. We used 16S rRNA amplicon sequencing to identify bacterial pathogens in the heart, liver, lungs, kidneys and spleen of 13 water voles (Arvicola terrestris) collected in Franche-Comté, France. We asked if bacterial pathogen assemblages within organs are similar and if all five organs are necessary to detect all of the bacteria present in an individual animal. We identified 24 bacteria representing 17 genera; average bacterial…

0301 basic medicineOperational taxonomic unitMESH: Sequence Analysis DNAEpidemiologyMESH : PrevalenceMESH : Tissue DistributionRodent DiseasesRNA Ribosomal 16Sbacterial pathogensPrevalenceMESH : DNA BacterialTissue DistributionMESH: AnimalsPathogen[SDV.EE]Life Sciences [q-bio]/Ecology environmenteducation.field_of_studybiologyEcologyArvicolinaeMicrobiotaMESH : Rodent Diseases3. Good healthMESH: RNA Ribosomal 16SInfectious DiseasesArvicolinaeFrancerodent-borne pathogenDNA Bacterial030106 microbiologyPopulationShort ReportZoology[ SDV.EE ] Life Sciences [q-bio]/Ecology environment03 medical and health sciencesAnimalsMESH: MicrobiotaMESH : BacteriaMESH: Tissue DistributionArvicola terrestriseducationMESH : FranceMESH: Prevalence[ SDE.BE ] Environmental Sciences/Biodiversity and EcologyBacteriaHost (biology)tissue selectionBacteria PresentSequence Analysis DNAMESH: Arvicolinaebiology.organism_classificationMESH: DNA BacterialMESH: FranceMESH : ArvicolinaeMESH : RNA Ribosomal 16SMESH: BacteriaHigh-Throughput Sequencing030104 developmental biologyMESH : MicrobiotaSpecies richnessMESH: Rodent DiseasesMESH : Animals[SDE.BE]Environmental Sciences/Biodiversity and EcologyBacteriaMESH : Sequence Analysis DNA
researchProduct

Prenatal Ambient Air Pollution, Placental Mitochondrial DNA Content, and Birth Weight in the INMA (Spain) and ENVIRONAGE (Belgium) Birth Cohorts

2016

The research leading to these results was funded by the Spanish Ministry of Health (FIS-PI11/00610, FIS-PI041436, FIS-PI081151, FIS-PI042018, and FIS-PI09/02311), the European Union (EU) (FP7-ENV-2011 cod 282957 and HEALTH.2010.2.4.5-1), the Instituto de Salud Carlos III (Red INMA G03/176, CB06/02/0041, FIS-FEDER 03/1615, 04/1509, 04/1112, 04/1931, 05/1079, 05/1052, 06/1213, 07/0314, 09/02647, 11/01007, 11/02591, CP11/00178, FIS-PI06/0867, and FIS-PS09/00090), the Conselleria de Sanitat Generalitat Valenciana, the Generalitat de Catalunya-CIRIT (1999SGR 00241), the Obre Social Cajastur, the Universidad de Oviedo, the Department of Health of the Basque Government (2005111093 and 2009111069),…

0301 basic medicinePediatrics:Phenomena and Processes::Physiological Phenomena::Body Constitution::Body Weights and Measures::Body Size::Body Weight::Birth Weight [Medical Subject Headings]:Phenomena and Processes::Physiological Phenomena::Physiological Processes::Growth and Development::Morphogenesis::Embryonic and Fetal Development::Fetal Development [Medical Subject Headings]Health Toxicology and MutagenesisPlacentaEspañaPhysiology:Diseases::Pathological Conditions Signs and Symptoms::Pathologic Processes::Growth Disorders::Fetal Growth Retardation [Medical Subject Headings]ADN mitocondrial010501 environmental sciencesMitochondrion01 natural sciencesFetal DevelopmentBélgicaPregnancyBirth Weightskin and connective tissue diseasesPeso al nacerNews | Science SelectionsMitocondrias:Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Reproductive Physiological Processes::Reproduction::Pregnancy [Medical Subject Headings]:Anatomy::Cells::Cellular Structures::Intracellular Space::Cytoplasm::Cytoplasmic Structures::Organelles::Mitochondria [Medical Subject Headings]2. Zero hunger:Geographicals::Geographic Locations::Europe::Spain [Medical Subject Headings]Air PollutantsAmbient air pollutionAire -- ContaminacióFemenino3. Good healthmedicine.anatomical_structureMaternal ExposureFemaleBirth cohort:Health Care::Environment and Public Health::Public Health::Environmental Pollution::Air Pollution [Medical Subject Headings]Mitochondrial DNAmedicine.medical_specialtyModelos LinealesEmbarazoBirth weightInfants -- DesenvolupamentBiology:Chemicals and Drugs::Inorganic Chemicals::Gases::Nitrogen Oxides::Nitrogen Dioxide [Medical Subject Headings]DNA Mitochondrial:Phenomena and Processes::Genetic Phenomena::Genetic Structures::Genome::Genome Components::Genes::Genes Mitochondrial [Medical Subject Headings]03 medical and health sciencesAir pollutantsPlacentaAir PollutionmedicineHumans:Geographicals::Geographic Locations::Europe::Belgium [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Models Statistical::Linear Models [Medical Subject Headings]Contaminación del aire0105 earth and related environmental sciencesRetardo del crecimiento fetal:Chemicals and Drugs::Nucleic Acids Nucleotides and Nucleosides::Nucleic Acids::DNA::DNA Circular::DNA Mitochondrial [Medical Subject Headings]Genes mitocondrialesPregnancyPublic Health Environmental and Occupational HealthDesarrollo fetalmedicine.disease:Anatomy::Embryonic Structures::Placenta [Medical Subject Headings]030104 developmental biology:Check Tags::Female [Medical Subject Headings]13. Climate actionSpainsense organsDióxido de nitrógeno
researchProduct

Eomes broadens the scope of CD8 T-cell memory by inhibiting apoptosis in cells of low affinity.

2020

The memory CD8 T-cell pool must select for clones that bind immunodominant epitopes with high affinity to efficiently counter reinfection. At the same time, it must retain a level of clonal diversity to allow recognition of pathogens with mutated epitopes. How the level of diversity within the memory pool is controlled is unclear, especially in the context of a selective drive for antigen affinity. We find that preservation of clones that bind the activating antigen with low affinity depends on expression of the transcription factor Eomes in the first days after antigen encounter. Eomes is induced at low activating signal strength and directly drives transcription of the prosurvival protein…

0301 basic medicinePhysiologyAntigenic Variation/immunologyApoptosisCD8 memory viral infection Eomesddc:616.07CD8-Positive T-LymphocytesLymphocyte ActivationEpitopeMemory T cellsMice0302 clinical medicineSpectrum Analysis TechniquesCognitionLearning and MemoryTranscription (biology)Immune PhysiologyReceptorsCellular typesCytotoxic T cellBiology (General)ReceptorClonal Selection Antigen-MediatedCell Survival/immunologyT-Cell/genetics/immunologyT-Lymphoid/immunologyCells CulturedFluorescence-Activated Cell SortingCulturedGeneral NeuroscienceImmune cellsFlow CytometryAntigenic VariationCell biologyProto-Oncogene Proteins c-bcl-2SpectrophotometryAntigenWhite blood cellsT-Box Domain Proteins/genetics/immunologyCytophotometrySignal transductionBIOMEDICINA I ZDRAVSTVO. Temeljne medicinske znanosti.General Agricultural and Biological SciencesApoptosis/immunologySignal TransductionResearch ArticleCell biologyBlood cellsQH301-705.5Precursor CellsCell SurvivalCellsImmunologyClonal SelectionReceptors Antigen T-CellT cellsCytotoxic T cellsBiologyCD8-Positive T-Lymphocytes/immunologyResearch and Analysis MethodsGeneral Biochemistry Genetics and Molecular BiologyAntigen-Mediated/genetics/immunology03 medical and health sciencesAntigenMemoryAnimalsMolecular Biology TechniquesTranscription factorMolecular BiologyMedicine and health sciencesPrecursor Cells T-LymphoidGene Expression Regulation/immunologyGeneral Immunology and MicrobiologyBiology and life sciencesBIOMEDICINE AND HEALTHCARE. Basic Medical Sciences.T-cell receptorProto-Oncogene Proteins c-bcl-2/genetics/immunology030104 developmental biologyGene Expression RegulationAnimal cellsCognitive ScienceT-Box Domain ProteinsImmunologic Memory030217 neurology & neurosurgerySpleenCloningNeurosciencePLoS biology
researchProduct

Epigenetic mutations can both help and hinder adaptive evolution.

2015

Epigenetic variation is being integrated into our understanding of adaptation, yet we lack models on how epigenetic mutations affect evolution that includes de novo genetic change. We model the effects of epigenetic mutations on the dynamics and endpoints of adaptive walks—a process where a series of beneficial mutations move a population towards a fitness optimum. We use an individual-based model of an asexual population, where mutational effects are drawn from Fisher's geometric model. We find cases where epigenetic mutations speed adaptation or result in populations with higher fitness. However, we also find cases where they slow adaptation or result in populations with lower fitness. Th…

0301 basic medicinePopulationAdaptation BiologicaladaptationBiologyEpigenesis Genetic03 medical and health sciencesevolutionGeneticsComputer SimulationEpigeneticseducationEcology Evolution Behavior and SystematicsGeneticseducation.field_of_studyFisher's geometric modelNatural selectionepigeneticsModels Geneticta1184Biological Evolution030104 developmental biologyPhenotypeEvolutionary biologyFisher's geometric modelMutationta1181genetic assimilationFitness effectsGenetic FitnessAdaptationGenetic assimilationAdaptive evolutionMolecular ecology
researchProduct

Cancer: a disease at the crossroads of trade-offs

2017

11 pages; International audience; Central to evolutionary theory is the idea that living organisms face phenotypic and/or genetic trade-offs when allocating resources to competing life-history demands, such as growth, survival, and reproduction. These trade-offs are increasingly considered to be crucial to further our understanding of cancer. First, evidences suggest that neoplastic cells, as any living entities subject to natural selection, are governed by trade-offs such as between survival and proliferation. Second, selection might also have shaped trade-offs at the organismal level, especially regarding protective mechanisms against cancer. Cancer can also emerge as a consequence of add…

0301 basic medicineReproduction (economics)[SDV.CAN]Life Sciences [q-bio]/CancerDiseaseBiologyTrade-offLife history theory[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesGeneticsmedicinecancertrade‐offEvolutionary dynamicsEcology Evolution Behavior and SystematicsSelection (genetic algorithm)ComputingMilieux_MISCELLANEOUSlife‐history traitsNatural selection[SDV.GEN.GPO]Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE]Ecology[SDV.BID.EVO]Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Cancernatural selectionmedicine.disease3. Good health[ SDV.GEN.GPO ] Life Sciences [q-bio]/Genetics/Populations and Evolution [q-bio.PE]030104 developmental biology[ SDV.BID.EVO ] Life Sciences [q-bio]/Biodiversity/Populations and Evolution [q-bio.PE]Evolutionary biologyGeneral Agricultural and Biological SciencesReviews and Syntheses
researchProduct